An impending deadline is coming up in early 2026 that could cause the country to lose its status. However, this can be reversible and unnecessary infections, severe disease, and deaths can be avoided. Rodney Rohde, PhD, talks about incidence rates, how we got here, and strategies to increase immunizations.
Margaret Aldrich, MD, provides insight around this concept, addressing stewardship within this patient population, and how their institution’s collaborative work environment helps all of the department’s clinicians.
Gilead Sciences reported positive phase 3 ARTISTRY-2 results demonstrating that a once-daily single-tablet combination of bictegravir and lenacapavir is statistically noninferior to bictegravir/emtricitabine/tenofovir alafenamide tablets in virologically suppressed adults with HIV. The company plans to file for regulatory submissions for approval.
With a novel, non–cross-resistant mechanism and phase 3 data showing noninferior efficacy to injectable standard therapy, zoliflodacin could become a novel treatment that expands clinician choice and strengthens global efforts to combat antimicrobial-resistant gonorrhea. Innoviva CMO David Altarac, MD, offers further insights about the newly-approved antibiotic and its potential place in the market.
This week, check out our coverage on 2 antibiotic FDA approvals, and clinicians weigh in on the ACIP recommendations on the hepatitis B virus (HBV) vaccine.
The antibiotic's approval was based from phase 3 results demonstrating noninferiority to a combination therapy.
Infectious disease pediatrician Sharon Nachman, MD, talks about how the new recommendations will defer immunization, leading to a whole host of issues and negative impacts on long-term public health.
GSK’s David Payne, PhD, provides more information are the data from the EAGLE-1 trial.
The federal nod was given based from the phase 3 data of the EAGLE-1 trial, which showed noninferiority to combination therapy. This approval provides a new oral option.
NYU Langone’s Angelica Cifuentes Kottkamp, MD, continues our Media Day discussion around these illnesses and how in New York City, clinicians need to be prepared to decipher in differential diagnosis for these potential diseases.
Reports are surfacing the federal agency is going to review products already reviewed and approved.
In episode 2 of our Media Day series with NYU Langone, Angelica Cifuentes Kottkamp, MD, discusses its vaccine center and their work around COVID-19 vaccines, as well as the importance of achieving diversity in clinical trials.
Robert Hopkins Jr, MD, medical director of the National Foundation for Infectious Diseases, discusses the changes in the new vaccine recommendations and what potential serious consequences may be seen as a result.
The federal agency approved Augmentin XR in just 2 months through the new CNPV pilot program, marking a potential step toward rebuilding domestic antibiotic manufacturing and addressing drug shortages.
Questions raised about unverified FDA claims linking COVID-19 vaccines to pediatric deaths, and concerns that proposed vaccine testing requirements could delay access to key immunizations.
A large meta-analysis indicates opioid exposure may disrupt immunity and gut microbiota, increasing CDI vulnerability and potentially worsening clinical outcomes.
Angelica Cifuentes Kottkamp, MD, discusses how its location, breadth of experience, and opportunities afford clinicians the ability to see and treat a wide berth of diseases and infections.
Most clinical isolates identified as triazole-resistant Aspergillus niger by traditional clinical laboratory methods were revealed by DNA sequencing to be A tubingensis.
Population study corroborates 2019 FDA alert based on case reports of acute respiratory failure with TMP-SMX in healthy adolescents and young adults.
This week, read our coverage on the CDC ACIP meetings on the hepatitis B virus (HBV) vaccine, modeling data on the potential consequences of HBV infections, liver cancer, and mortality when delaying the birth dose to 2 months, our latest podcast, and more.
Lacking any safety data showing potential serious adverse effects, the committee decided to move forward with the recommendation “that the initial dose is administered no earlier than 2 months of age.”
Due to repetitive and confusing language, the committee decided to amend the votes for clarity and will vote on 3 new recommendations on Friday.
Anticipating possible constraints on the approval of COVID-19 vaccines and their removal from the CDC pediatric vaccine schedule, a medical ethicist and legal scholar consider off-label vaccination.
A public health and farmworker coalition says agricultural spraying of medically important antibiotics and antifungals contributes to environmental resistance and warrants EPA cancellation.
New Centers for Disease Control and Prevention (CDC) data show rising early-season influenza activity, moderate 2024–2025 vaccine effectiveness, and updated 2025–2026 recommendations that include trivalent, thimerosal-free single-dose formulations and expanded access to FluMist.
A new analysis shows thousands of children could contract hepatitis B, leading to further complications and deaths, if the vaccine schedule recommendations are changed to later in a child's life.
Improving public awareness of appropriate antibiotic use could complement antibiotic stewardship programs worldwide.
WHO and UNAIDS warn of service disruptions, widening inequities, and mounting drug-resistance threats, while highlighting innovations and commitments needed to end AIDS as a public health threat.
In our latest podcast, Elizabeth Marlowe, PhD, D(ABMM), discusses the findings of Quest Diagnostics' large US HIV testing study, which showed a significant decline in HIV drug resistance across major antiretroviral classes, reflecting the impact of modern high-barrier therapies and improved viral suppression.
The New Jersey company recently announced the partnership that includes federal funding to create new treatments from a novel class of fungerps.
